Annemarie D. V.
- Country
- The Netherlands
- Department
- Gastroenterology and Hepatology
Research Overview
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Study Evaluating Efficacy and Safety of JNJ‑78934804 Combination Therapy versus Guselkumab in Moderately to Severely Active Crohn’s Disease
Data & Insights
Has run more than one trial at 272 of 414 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating inflammatory bowel disease, with particular emphasis on novel therapeutic approaches and disease management strategies.
- Vedolizumab therapy optimization
- Subcutaneous treatment administration
- Dose modification strategies
The research explores innovative treatment protocols in IBD care.
Crohn's Disease Research
Focus areas include advanced treatments for Crohn's disease, particularly complex manifestations such as fistulizing perianal disease.
- Transmural healing approaches
- Combination therapy evaluation
- Perianal fistula management
The investigator examines both established and emerging therapeutic options for various disease presentations.
Ulcerative Colitis Studies
Research interests extend to treating moderately to severely active ulcerative colitis through innovative therapeutic combinations.
- Combined biological therapies
- Treatment optimization strategies
- Long-term disease management
Investigation focuses on comparative effectiveness of monotherapy versus combination approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.